Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously
funded under SBIR or STTR Phase II awards from any Federal agency.
The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage.
This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.
Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period.
It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period.
Proposed projects may address preclinical and/or clinical stages of technology development.
Clinical trials may be proposed as appropriate but are not required.
The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage.
This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.
Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period.
It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period.
Proposed projects may address preclinical and/or clinical stages of technology development.
Clinical trials may be proposed as appropriate but are not required.
Related Programs
Department of Health and Human Services
Cancer Detection and Diagnosis Research
Department of Health and Human ServicesDepartment of Health and Human Services
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $16,000,000
Office: National Institutes of Health
Estimated Funding: $16,000,000
Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-022.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-022.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2024-04-23
Application Due Date:
Archive Date:
2024-09-26
Social Entrepreneurship
Spotlight
Social Enterprises Impact 100,000 lives in 2015
A Research Report has shown a positive outlook for Social Enterprises in Ghana with the current support systems by government and other development partners, including the British Council.
Learn How to Identify and Avoid Grant Scams
